KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Recursion Pharmaceuticals (RXRX) Shares Issued: 2020-2025

Historic Shares Issued for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $254.5 million.

  • Recursion Pharmaceuticals' Shares Issued rose 1399.65% to $254.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.5 million, marking a year-over-year increase of 10.62%. This contributed to the annual value of $300.4 million for FY2024, which is 134.53% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Shares Issued of $254.5 million as of Q3 2025, which was up 154.46% from $100.0 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Shares Issued registered a high of $460.7 million during Q2 2021, and its lowest value of $1.9 million during Q1 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Shares Issued value was $41.0 million (recorded in 2025), while the average stood at $74.9 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Shares Issued skyrocketed by 13,362.50% in 2021, and later slumped by 99.42% in 2022.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Shares Issued stood at $460.7 million in 2021, then tumbled by 99.42% to $136.6 million in 2022, then slumped by 42.81% to $78.1 million in 2023, then slumped by 85.88% to $11.0 million in 2024, then surged by 1,399.65% to $254.5 million in 2025.
  • Its last three reported values are $254.5 million in Q3 2025, $100.0 million for Q2 2025, and $41.0 million during Q1 2025.